Pair Name	alpha-Hydroxylinoleic acid, Paclitaxel
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Autophagy
Gene Regulation	Down-regulation	Expression	MAP1LC3A	hsa84557
	Up-regulation	Expression	MAP1LC3B	hsa81631
	Up-regulation	Expression	TRIB3	hsa57761
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
Result	ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.

Pair Name	alpha-Hydroxylinoleic acid, Paclitaxel
Disease Info	[ICD-11: 2C25.Z]	Lung cancer		Investigative
Biological Phenomena	Induction-->Autophagy
Gene Regulation	Down-regulation	Expression	MAP1LC3A	hsa84557
	Up-regulation	Expression	MAP1LC3B	hsa81631
	Up-regulation	Phosphorylation	PRKAA1	hsa5562
	Down-regulation	Expression	AKT1	hsa207
	Up-regulation	Expression	TRIB3	hsa57761
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
	NCI-H1975	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_1511
	NCI-H157	Lung squamous cell carcinoma	Homo sapiens (Human)	CVCL_0463
	NCI-H520	Lung squamous cell carcinoma	Homo sapiens (Human)	CVCL_1566
Result	The safety profile of ABTL0812 and its good synergy with chemotherapy potentiate the therapeutic potential of current lines of treatment based on chemotherapy regimens, arising as a promising option for improving these patients therapeutic expectancy.